Test drug given by IV for hard-to-treat rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This early study (Phase 1) tests the safety and tolerability of BX-U001 given through an IV infusion in people with rheumatoid arthritis (RA) that has not improved with standard treatments. It looks for side effects and how well the body handles the drug, which may guide future studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 70
- You have rheumatoid arthritis for more than 6 months
- You tried common RA medicines but they did not work or you could not tolerate them
- You are currently on stable RA medicine (one of the listed options) for at least 3 months, with no dose changes for at least 6 weeks
- Your RA is active: you have enough joint swelling/pain, and your blood inflammation marker (CRP) is above normal
- You have RA blood tests positive for rheumatoid factor and/or anti-CCP, and you are otherwise clinically stable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This trial tests an experimental drug for people with rheumatoid arthritis who have not had success with other treatments. It aims to see if the drug can help reduce joint pain and swelling.
This trial tests a new treatment called SWK002 for people with rheumatoid arthritis that hasn't improved after trying multiple medications. It aims to see if SWK002 can help when other treatments have failed.
This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.
This trial tests a new experimental antibody called GNC-038 for people with moderate to severe rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if targeting specific immune cells can reduce inflammation and improve symptoms.
This study tests a new drug called HBM7020 to see how safe it is and how your body processes it. The trial includes healthy volunteers and people with autoimmune diseases like lupus, rheumatoid arthritis, or scleroderma to understand if the drug might help reduce disease activity.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.